Perinatal transmission and cure of extensively drug-resistant tuberculosis in an infant
Article Sidebar
Main Article Content
Abstract
We describe a rare case of perinatally acquired extensively drug-resistant tuberculosis in an infant. The infant was successfully treated with an individualised all-oral multidrug regimen containing delamanid, a drug rarely described in the treatment of perinatal tuberculosis.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. World Health Organization. Global tuberculosis report 2023. Geneva: WHO, 2023.
https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-
reports/global-tuberculosis-report-2023 (accessed 10 June 2024).
2. World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. 27-29 October 2020. Geneva: WHO, 2020. https://www.who.int/publications/i/item/9789240018662 (accessed
10 June 2024).
3. Shenoi A, Kavitha A. Perinatal tuberculosis. Pediatr Infect Dis 2019;1(1):30-33.
https://doi.org/10.5005/jp-journals-10081-1107
4. Singh M, Kothur K, Dayal D, Kusuma S. Perinatal tuberculosis: A case series. J Trop Pediatr 2007;53(2):135-138. https://doi.org/10.1093/tropej/fml074
5. Cantwell MF, Shehab ZM, Costello AM, et al. Brief report: Congenital tuberculosis. N Engl J Med 1994;330(15):1051-1054. https://doi.org/10.1056/ NEJM199404143301505
6. WorldHealthOrganization.WHOconsolidatedguidelinesontuberculosis.Module5: Management of tuberculosis in children and adolescents. Geneva: WHO, 2022. https://www.who.int/publications/i/item/9789240046764 (accessed 12 June 2024).
7. National Department of Health, South Africa. Clinical management of rifampicin- resistant tuberculosis: Updated clinical reference guide. Pretoria: NDoH, 2023. https:// knowledgehub.health.gov.za/elibrary/clinical-management-rifampicin-resistant- tubercolosis (accessed 12 June 2024).
8. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: Prevention – tuberculosis preventive treatment. Geneva: WHO, 2024. https://www. who.int/publications/i/item/9789240096196 (accessed 13 September 2024).
9. Boast A, How JA, Lau C, et al. Pre-extensively drug-resistant congenital tuberculosis in an extremely premature baby. Clin Infect Dis 2024;78(1):149-153. https://doi. org/10.1093/cid/ciad540
10. Espiritu N, Aguirre L, Jave O, Sanchez L, Kirwan DE, Gilman RH. Congenital transmission of multidrug-resistant tuberculosis. Am J Trop Med Hyg 2014;91(1):92-95. https://doi.org/10.4269/ajtmh.13-0002